The concept of control in COPD: A new proposal for optimising therapy

European Respiratory Journal

Volumn 44, Issue 4, 2014, Pages 1072-1075

  Soler Cataluña, Juan José ^a,b   Alcázar Navarrete, Bernardino ^c   Miravitlles, Marc ^b,d  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Hospital de Alta Resolucion   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AIRWAY OBSTRUCTION; ASTHMA; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EXERCISE; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; LUNG FUNCTION; PHENOTYPE; PHYSICAL ACTIVITY; PROGNOSIS; QUALITY OF LIFE; TREATMENT RESPONSE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 84907555995     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00064414     Document Type: Letter

References (14)

1. Agusti A, MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax 2013; 68: 687-690.
2. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J 2013; 41: 1252-1256.
3. McDonald V, Higgins I, Wood LG, et al. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax 2013; 68: 691-694.
4. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604.
5. Celli BR, Cote CG, Marín JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.
6. Soler-Cataluña JJ, Martínez-García MA, Sánchez L, et al. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 2009; 103: 692-699.
7. Agustí A, Calverley PMA, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.
8. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648-654.
9. Van der Molen T, Willemse BWM, Schokker S, et al. Development, validity and responsiveness of the clinical COPD questionnaire. Health Qual Life Outcomes 2003; 1: 13.
10. Agustí A, Soler JJ, Molina J, et al. Is the CAT questionnaire sensitive to changes in health status in patients with severe COPD exacerbations? COPD 2012; 9: 492-498.
11. Miravitlles M, García-Sidro P, Fernández-Nistal A, et al. Course of COPD assessment test (CAT) and clinical COPD questionnaire (CCQ) scores during recovery from exacerbations of chronic obstructive pulmonary disease. Health Qual Life Outcomes 2013; 11: 147.
12. Kon SSC, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med 2014; 2: 195-203.
13. Kocks JWH, Tuinenga MG, Uil SM, et al. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res 2006; 7: 62.
14. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD. Arch Bronconeumol 2012; 48: 247-257.